A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Stopped early · Phase 1
Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndromes
In brief
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
Key facts
- Study ID
- NCT04477291
- Run by
- Aptose Biosciences Inc.
- People needed
- 45
- Starts
- 2020-10-06
- Expected to finish
- 2024-04-15
- Last updated by the study team
- 2025-03-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope National Medical Center — Duarte, California, United States
- University of Southern California — Los Angeles, California, United States
- University of Miami — Miami, Florida, United States
- Northwestern University — Chicago, Illinois, United States
- Ochsner Healthcare — New Orleans, Louisiana, United States
- Atlantic Hematological Oncology Center — Morristown, New Jersey, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- University Hospital of Cleveland — Cleveland, Ohio, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.